Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) is a pharmaceutical company that is dedicated to preventing and treating gastrointestinal diseases. They aim to provide the most effective solutions to their patients. The company is currently doing studies to examine the effect of 550 mg rifaximin TID on patients that are suffering from IBS-D – Irritable Bowel Syndrome with Diarrhea. The trials are being performed on patients who previously responded to the drug over the course of an early treatment that was carried out for 14 days. The current study is called Target 3. It is placebo-controlled and double-blind. The purpose of this Phase III, randomized study is to determine that whether a repeat treatment of the patients, suffering from IBS-D, with 550 mg rifaximin TID will be safe and efficacious. Target 3 is also a 14-day trial.

However, today, Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) reported successful outcomes of Target 3. The company claimed to the press that a statistically larger number of patients with IBS-D showed response to the repeat treatment of rifaximin 550 mg TID, as opposed to those treated with the placebo. During the PEP, Primary Evaluation Period, which is a four week follow-up period without any treatment, the subjects were assessed based on their stool consistency and abdominal pains. Thanks to the successful outcome of Target 3, the shares of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) increased 13%, which was a new high for the company.

Stratasys, Ltd. (NASDAQ:SSYS) provides equipment for 3-D printing and material that allows one to create physical items from the digital data available. The systems offered by the company span a wide range – you can either avail their desktop 3-D printing machines or entire production systems. On July 1^st, 2014, Stratasys, Ltd’s (NASDAQ:SSYS) stocks for 3-D Printing were seeing nothing but rise. This was all thanks to the reports that claimed that these printers can be potentially used in the field of medicine.

Agenus Inc (NASDAQ:AGEN) is a company that specializes in the discovery and development of immunotherapeutics. Currently, the company is in the course of performing Phase II trials on patients of glioblastoma multiforme or GBM. GBM is a very aggressive and most common brain tumor. Its treatment involves surgery, radio –therapy and chemo-therapy. The patients were recently diagnosed with GBM. They were provided standard care treatment and were given the trial drug Agenus Prophage, the autologous vaccine for cancer. This study is open-label and involves the collaboration of multiple institutions. It was a big leap towards success for Agenus Inc when the results of the study showed that the patients who were treated with the cancer vaccine were expected to live two times as much as their expected lifetime. Cancer frequently kills its patients within a year. However, the single-arm, Phase II study has shown that about half of the treated patients lived up to two years, which is a highly encouraging result. Consequently, Agenus Inc (NASDAQ:AGEN) gained 10.98% after the results of the study were proclaimed.

Also, the study shows that the treated patients have an average survival of 24 months. Almost 33% of the patients are still kicking after 2 years. The company is keeping their tracks for survival.

Get Free Updates and Stock Alerts!

*We only send one email per week